Treatment of Small Intestine Bacterial Overgrowth with Rifaximin, a Non-Absorbable Rifamycin
- 1 July 1988
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 16 (4) , 312-316
- https://doi.org/10.1177/030006058801600410
Abstract
In twelve patients affected by small bowel bacterial overgrowth, diagnosed by means of the lactulose hydrogen breath test, the therapeutic efficacy of a non-absorbable derivative of rifamycin, rifaximin, was evaluated. This study showed that this drug has a satisfactory therapeutic efficacy in contaminated small bowel syndrome and, at the doses tested, is free of side-effects.This publication has 13 references indexed in Scilit:
- Influence of the oropharyngeal microflora on the measurement of exhaled breath hydrogenGastroenterology, 1986
- Bacterial contamination of the small intestine is an important cause of occult malabsorption in the elderly.BMJ, 1983
- Small-Bowel Bacterial Overgrowth in the Postgastrectomy SyndromeScandinavian Journal of Gastroenterology, 1983
- Pharmacokinetics of L/105, a New Rifamycin, in Rats and Dogs, after Oral AdministrationChemotherapy, 1983
- Severe diarrehoea due to small intestinal colonisation during cimetidine treatment.BMJ, 1980
- The contaminated small bowel syndromeThe American Journal of Medicine, 1979
- Small Intestine Bacterial OvergrowthGastroenterology, 1979
- The Lactulose Hydrogen Breath Test as a Diagnostic Test for Small-Bowel Bacterial OvergrowthScandinavian Journal of Gastroenterology, 1979
- Diabetic Diarrhea and SteatorrheaAnnals of Internal Medicine, 1970